Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Cytarabine, Depocyt. Every FDA application for this active ingredient: 2 branded and 21 generic.
As of Nov 16, 2026, FDA lists 23 applications for Cytarabine (sold as Cytarabine, Depocyt), first approved Jun 17, 1969, with 1 new use approved and 0 published complete response letters.
First approved: Jun 17, 1969
Applications: 23
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $8K
First approved in the EU: Jul 11, 2001
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Cytarabine
Part B
$5K
-32%
115
Cytarabine
Part D
$3K
-15%
81
Approvals in the EU (EMA)
First approved in the EU 385 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
CylocideDrugs with a new dosage indicated for the treatment of acute leukemia. · Nippon Shinyaku Co., Ltd. · May 25, 2023
Cylocide NDrugs with a new indication and a new dosage for the treatment of acute leukemia. · Nippon Shinyaku Co., Ltd. · May 25, 2023
CylocideDrugs with a new dosage indicated for the treatment of acute leukemia (including erythroleukemia and blast crisis of chronic myeloid leukemia). · Nippon Shinyaku Co., Ltd. · Aug 21, 2020
Cylocide NDrugs with other characteristics indicated for the treatment prior to tumor-specific T-cell infusion therapy. · Teva Takeda Pharma Ltd. · Mar 26, 2019
CylocideDrugs with a new route of administration indicated for the treatment of acute leukemia (including acute erythroid leukemia and blast crisis of chronic… · Nippon Shinyaku Co., Ltd. · Dec 18, 2014
Clinical Trials
416 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA